Online inquiry

IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4247MR)

This product GTTS-WQ4247MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets Factor VIII substitute gene. The antibody can be applied in Hemophilia A research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000132.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2157
UniProt ID P00451
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4247MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4094MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BI-204
GTTS-WQ13253MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ12511MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ13967MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ14510MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ3579MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1112623(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1112623
GTTS-WQ11785MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ11917MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MLN2045
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW